Elanco Animal Health Incorporated Increase (Decrease) in Operating Capital
Elanco Animal Health Incorporated (ELAN) reported Increase (Decrease) in Operating Capital of $239.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingCapital · last filed 2026-08-05
- Elanco Animal Health Incorporated increase (decrease) in operating capital for the quarter ending 2026-06-30 was -$24.00M.
- Elanco Animal Health Incorporated increase (decrease) in operating capital for the quarter ending 2026-03-31 was $263.00M, a 10.97% increase year-over-year.
- Elanco Animal Health Incorporated increase (decrease) in operating capital for the quarter ending 2025-09-30 was -$59.00M.
- Elanco Animal Health Incorporated increase (decrease) in operating capital for the quarter ending 2025-06-30 was -$52.00M.
| Period end | Increase (Decrease) in Operating Capital 3 month | Increase (Decrease) in Operating Capital 3 month as first filed | Increase (Decrease) in Operating Capital 6 month | Increase (Decrease) in Operating Capital 6 month as first filed | Increase (Decrease) in Operating Capital 9 month | Increase (Decrease) in Operating Capital 9 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$24.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $239.00M 10-Q · filed 2026-08-05 | ||||
| 2026-03-31 | $263.00M 10-Q · filed 2026-05-06 | |||||
| 2025-09-30 | -$59.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$111.00M derived: sum of 2 quarters · filed 2026-08-05 | $126.00M 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | -$52.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $185.00M 10-Q · filed 2026-08-05 | ||||
| 2025-03-31 | $237.00M 10-Q · filed 2026-05-06 | |||||
| 2024-09-30 | -$248.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$270.00M derived: sum of 2 quarters · filed 2025-11-05 | -$93.00M 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | -$22.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $155.00M 10-Q · filed 2025-08-07 | ||||
| 2024-03-31 | $177.00M 10-Q · filed 2025-05-07 | |||||
| 2023-09-30 | -$27.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $7.00M derived: sum of 2 quarters · filed 2024-11-07 | $446.00M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $34.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $473.00M 10-Q · filed 2024-08-08 | ||||
| 2023-03-31 | $439.00M 10-Q · filed 2024-05-08 | |||||
| 2022-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $53.00M derived: sum of 2 quarters · filed 2023-11-07 | $385.00M 10-Q · filed 2023-11-07 | $384.00M 10-Q · filed 2022-11-08 | ||
| 2022-06-30 | $52.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $384.00M 10-Q · filed 2023-08-07 | $369.00M 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | $332.00M 10-Q · filed 2023-05-09 | $331.00M 10-Q · filed 2022-05-09 | ||||
| 2021-09-30 | $53.00M derived: 10-K 9 month − 10-K 6 month · filed 2023-03-01 | $59.00M derived: sum of 2 quarters · filed 2023-03-01 | $243.00M 10-K · filed 2023-03-01 | |||
| 2021-06-30 | $6.00M derived: 10-K 6 month − 10-K 3 month · filed 2023-03-01 | $190.00M 10-K · filed 2023-03-01 | ||||
| 2021-03-31 | $184.00M 10-K · filed 2023-03-01 | $183.00M 10-Q · filed 2021-05-07 | ||||
| 2020-09-30 | -$85.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | -$301.00M derived: sum of 2 quarters · filed 2021-11-05 | -$291.00M 10-Q · filed 2021-11-05 | -$290.90M 10-Q · filed 2020-11-06 | ||
| 2020-06-30 | -$216.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$206.00M 10-Q · filed 2021-08-09 | -$205.70M 10-Q · filed 2020-07-30 | |||
| 2020-03-31 | $10.00M 10-Q · filed 2021-05-07 | $9.80M 10-Q · filed 2020-05-07 | ||||
| 2019-09-30 | $61.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $149.80M derived: sum of 2 quarters · filed 2020-11-06 | $267.00M 10-Q · filed 2020-11-06 | |||
| 2019-06-30 | $88.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $205.20M 10-Q · filed 2020-07-30 | ||||
| 2019-03-31 | $117.20M 10-Q · filed 2020-05-07 | |||||
| 2018-09-30 | -$14.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $83.40M 10-Q · filed 2019-11-08 | ||||
| 2018-06-30 | $98.30M 10-Q · filed 2019-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |